Table 2.

Cox models were used to estimate the effect of different anti-hypertensive therapies on infectious, inflammatory and structural outcomes

	Infectious (N = 21,523)	Inflammatory (N = 50,449)	Structural (N = 42,615)
ACE-I vs Control
Model 1 (Initial Drug)
HR	0.886	0.924	0.865
95%CI	0.859–0.886	0.906–0.942	0.847–0.885
p	<0.0001	<0.0001	<0.0001
NNT	240	156	104
Model 2 (Drug duration)
Est	−0.0041	−0.0034	−0.031
p	<0.0001	<0.0001	<0.0001
ARB vs Control
Model 1 (Initial Drug)
HR	0.957	0.970	0.900
95%CI	0.914–1.009	0.940–1.001	0.868–0.933
p	0.1067	0.0568	<0.0001
NNT	637	395	140
Model 2 (Drug duration)
Est	−0.0050	−0.0033	−0.036
p	<0.0001	<0.0001	<0.0001

Model 1 uses the first drug prescribed and follows the incidence of diagnosis up until the patient stops taking the medication. Model 2 takes into account the duration of the treatment in order to compare to emergence of disease. Diabetic-status, Flu Vaccine and Statin use are corrected for in each analysis comparing anti-hypertensive therapy. The number needed to treat (NNT) was also calculated for ACE-I and ARB use for infectious, inflammatory or structural outcomes